Xcout Intel
ALZHEON, INC. competitors & alternatives
The 12 closest competitors and alternatives to ALZHEON, INC. among biotechnology companies — ranked by similarity to what ALZHEON, INC. actually does, not by market-cap band.
Subscribe to see ALZHEON, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ALZHEON, INC.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
ALZHEON, INC. at a glance
ALZHEON, INC. is a biotechnology company headquartered in United States, founded in 2013. Its most recent funding round raised $78.8M in August 2026. Xcout tracks 13 named people at ALZHEON, INC., including Martin Tolar, M.D., Ph.D. (President and Chief Executive Officer).
ALZHEON, INC. leadership
- Martin Tolar, M.D., Ph.D.President and Chief Executive Officer
- Adem AlbayrakExecutive Officer
- Aidan Power, MRCPsychExecutive Officer
- John Hey, Ph.D.Executive Officer
- Kenneth MaceExecutive Officer
- Martin Tolar, M.D., Ph.D.Executive Officer
7 more named people on record for ALZHEON, INC., with roles, board committees and tenure — see the full roster →
ALZHEON, INC. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $78.8M | — | |
| Series E | $125M | 1 named | |
| Series E | $100M | 1 named | |
| SEC Form D filing | $126.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent ALZHEON, INC. news
- FundingPrivate placement (Form D)
Top 12 ALZHEON, INC. competitors
Ranked by semantic similarity — how close each company is to ALZHEON, INC. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Similar biotechnology company
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Life Sciences
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Life Sciences
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Similar biotechnology company
Avraham Pharmaceuticals Ltd. is a biotechnology company headquartered in Yavneh, Israel, founded in 2010. The company develops novel small molecule drugs and multi-functional drug substances, such as ladostigil, aimed at the treatment and prevention of neurodegenerative disorders and mild cognitive impairment.
Biotech
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Biotech
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Similar biotechnology company
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Biotech
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Similar biotechnology company
Vigil Neuroscience is a biotechnology company headquartered in Massachusetts that harnesses the power of microglia for the treatment of neurodegenerative diseases.
Similar biotechnology company
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Similar biotechnology company
Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ALZHEON, INC. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ALZHEON, INC.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →